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ABSTRACT

THE EFFECT OF PERICYTE CELL THERAPY ON POSTISCHEMIC
NEOVASCULARIZATION IN WILD TYPE AND TYPE 2 DIABETIC MICE
MAY 2017
KATHERINE L. HAYES, B.S., DREXEL UNIVERSITY
M.S., UNIVERSITY OF NEW HAMPSHIRE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Sarah Witkowski, PhD

Peripheral artery disease is an atherosclerotic disease that causes limb
ischemia and has few effective treatments. Stem cell therapy is a promising
treatment option, but concomitant diabetes may limit its effectiveness. The purpose
of this study was to evaluate the therapeutic potential of skeletal muscle pericytes to
augment postischemic neovascularization following the induction of limb ischemia
in wild type and type 2 diabetic (T2DM) mice. The hypothesis was that diabetes
impairs the ability of skeletal muscle pericytes to augment postischemic
neovascularization and differentiate in vivo. Pericytes were isolated via fluorescence
activated cell sorting for CD45-CD34-CD146+ cells, and pericyte phenotype was
confirmed via surface marker expression, gene expression, and in vitro
differentiation potential. Wild type C57BL/6 (n=12) and leptin receptor deficient
db/db T2DM (n=10) mice underwent unilateral femoral artery ligation to induce
limb ischemia. Twenty-four hours post-ligation, pericytes or vehicle control were
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transplanted into the muscles of the ischemic hindlimbs. Postischemic
neovascularization was assessed via foot blood flow at pre-surgery, post-surgery,
and postoperative days 3, 7, 14, 21, and 28 using laser Doppler perfusion imaging.
Differences in gene expression were determined using t-tests; differences in blood
flow were determined using linear mixed models. CD45-CD34-CD146+ pericytes
were positive for mesenchymal stem cell markers CD90 (74%) and CD105 (65%)
and weakly positive for the pericyte marker PDGFRβ (42%) and the endothelial cell
marker CD144 (36%). Pericytes transdifferentiated into skeletal myocytes,
adipocytes, osteocytes, and endothelial cells in vitro. Pericytes had significantly
(p<0.05) upregulated Sca1 (4.0-fold) gene expression, downregulated CD31 (0.2fold) gene expression, and no difference in MyoD (1.0-fold), Pax3 (1.3-fold), or Pax7
(1.0-fold) expression. Blood flow recovery in wild type mice was significantly higher
after pericyte transplantation than after vehicle control (p=0.04; 79.3±5% vs.
61.9±5% at postoperative day 28). Blood flow recovery in T2DM mice after pericyte
transplantation was not different than after vehicle control (p=0.51; 48.6% vs.
46.3±5% at postoperative day 28). There was no effect of pericyte transplant on
angiogenesis in wild type or T2DM mice. Pericyte transplantation enhanced
collateral artery enlargement compared to control transplantation in wild type
(26.7±2 μm vs. 22.3±1 μm, p=0.03), but not T2DM mice (20.4±1.4 μm vs. 18.5±1.2
μm, p=0.14). In vivo, there was greater pericyte incorporation into collateral arteries
in wild type than in T2DM mice; and transplanted pericytes differentiated into
Schwann cells in both wild type and T2DM mice. In conclusion, T2DM impairs the
ability of pericytes to augment neovascularization via decreased collateral artery
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enlargement and impaired engraftment into collateral vessels. Further study is
required to determine the mechanism by which T2DM impairs pericyte cell therapy.
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CHAPTER 1
INTRODUCTION

Peripheral artery disease (PAD) is an atherosclerotic occlusive disease that
most commonly manifests with limb ischemia. Although the prevalence of many
cardiovascular diseases is on the decline, the prevalence of PAD has risen by
approximately 24% worldwide from 2000 to 2010 and now affects over 200 million
people 1, 2. The prevalence of type 2 diabetes (T2DM) is also increasing, and diabetes
is the most powerful risk factor for the development of PAD. People with PAD
experience pain, poor mobility, decreased quality of life, and increased risk of allcause mortality with no pharmaceutical options or limited options for surgical
revascularization. Thus, much hope exists for the development of an effective
cellular therapy as an alternative to the existing invasive open surgical or catheterbased PAD treatment paradigms.
Pericytes are a novel therapeutic target for a PAD cell therapy, and they have
distinct advantages as a therapeutic strategy for the treatment of symptomatic PAD.
Pericyte are located in a periendothelial position along the microvasculature,
including pre-capillary arterioles, capillaries, and post-capillary venules. They are
tissue resident cells that are crucial for angiogenesis via interactions with
endothelial cells 3, 4. They may also be advantageous during postischemic
neovascularization through transdifferentiation into terminal cells 3, 5, including
skeletal myocytes 6-8 and endothelial cells 9. These advantages, especially their
multipotent differentiation potential, provide a mechanism by which they might
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restore blood flow to an injured tissue. However, pericytes may be dysfunctional in
T2DM. Before they can be exploited for a cellular therapy to treat PAD, the effect of
diabetes on pericyte function during postischemic neovascularization must be
evaluated.
Diabetes and PAD often occur together; furthermore, the natural course of
PAD is worse in diabetics. This is important because the diabetic environment has
been shown to diminish the therapeutic potential of stem cells for the treatment of
PAD. Evidence suggests that mesenchymal stem cells (MSCs) have diminished
capacity to promote postischemic neovascularization in T2DM mice10. The reduced
function of MSCs in diabetic mice was shown to be due in part to reduced
differentiation capacity10. However, no studies to date have evaluated skeletal
muscle pericytes as a therapeutic strategy to treat PAD in diabetics. This
dissertation project addressed this knowledge gap by testing the efficacy of skeletal
muscle pericyte therapy to rescue the impaired postischemic neovascularization in
a clinically relevant model of PAD and T2DM.
The scientific goal of this dissertation was to determine the effect of pericyte
cell therapy on postischemic neovascularization after induction of hindlimb
ischemia in wild type and T2DM mice. To test the central hypothesis that diabetes
impairs the ability of skeletal muscle-derived pericytes to increase postischemic
neovascularization after induction of hindlimb ischemia via impaired differentiation
into skeletal myocytes and endothelial cells, the following aims and hypotheses
were examined:
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Specific Aims
1. To determine the effect of skeletal muscle pericyte cell therapy on postischemic
neovascularization induced by hindlimb ischemia in vivo in wild type and T2DM
mice. Wild type C57BL/6 and leptin-receptor deficient db/db (T2DM) mice
underwent unilateral femoral artery ligation surgery to induce hindlimb ischemia
followed by intramuscular injection of GFP+ pericytes or vehicle control into the
ischemic hindlimb. Neovascularization was assessed via limb blood flow recovery,
angiogenesis, and arteriogenesis (collateral artery enlargement) at 28 days postinduction of ischemia. We hypothesized that pericyte cell therapy improves
neovascularization in wild type recipients compared to control mice, but that T2DM
impairs the efficacy of pericyte cell therapy to enhance postischemic
neovascularization.

2. To determine the in vivo rate of pericyte differentiation into endothelial cells and
skeletal myocytes during neovascularization after induction of hindlimb ischemia in
wild type and T2DM mice. Surgical and transplantation methods from Aim 1 were
used to address Aim 2. Pericyte differentiation into skeletal myocyte or endothelial
cell phenotypes was assessed using immunohistochemistry. We hypothesized that
the diabetic environment impairs pericyte differentiation into endothelial cells and
skeletal myocytes compared to the wild type recipient environment.
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CHAPTER 2
LITERATURE REVIEW
Peripheral artery disease is an atherosclerotic occlusive disease that most
commonly manifests with limb ischemia. The main symptom of ischemia is pain in
the affected limbs, which initially presents only during physically activity, known as
intermittent claudication, but can progress to pain during rest, known as critical
limb ischemia. PAD negatively impacts physical functioning and quality of life, and it
is associated with an increased risk of death from cardiovascular disease. As an
atherosclerotic disease, inflammation is key in the initiation and progression of the
disease. Additionally, concomitant disease, such as T2DM, contributes to the
inflammatory environment and may negatively impact the efficacy of cellular
therapies for PAD. Therefore, the effect of T2DM on the ability for cellular therapies
to promote vascular remodeling and the restoration of blood flow to ischemic
tissues should be examined. While many candidate cell types may be employed as a
therapeutic to support vascular remodeling, including angiogenesis and
arteriogenesis, the goal of this proposal is to determine the efficacy of pericyte cell
therapy on postischemic neovascularization following experimentally induced limb
ischemia in wild type or T2DM mice.

Peripheral artery disease
PAD is a vascular disease that is characterized by atherosclerosis in
noncoronary arteries, most commonly affecting the legs. Approximately 8.5 million
Americans over the age of 40 years suffer from PAD with a disproportionate amount
4

of older adults and African Americans being affected11. Globally, PAD is an important
public health concern. The prevalence of PAD is increasing worldwide despite an
overall decrease in cardiovascular disease prevalence. From 2000-2010, the
prevalence of PAD increased by approximately 24% worldwide, and now affects
over 200 million people1, 2. In the United States alone, over $4.3 billion were spent
on PAD-related treatment for elderly non-disabled Medicare patients in 200112. The
global cost for PAD treatment is even greater, and the economic burden is increasing
as disease prevalence continues to rise.
The risk factors for PAD are similar to those for coronary heart disease, and
the most powerful predictors for PAD development include smoking and diabetes
mellitus2, 13. Epidemiological evidence from the Framingham Heart Study indicates
that 1 in 5 people with symptomatic PAD also have diabetes, although this is likely
an underestimate of the number of PAD patients with a diabetic comorbidity
because PAD is often asymptomatic14. Other studies indicate that the prevalence of
diabetes in PAD patients is approximately 50 percent15, 16.
Diabetes compounds complications from PAD. PAD patients with diabetes
have greater disease severity and are at a greater risk of limb amputation17.
Peripheral neuropathy that results from uncontrolled diabetes masks the symptoms
of PAD, meaning that people with diabetes often do not seek treatment for PAD until
they have advanced disease, including severe pain, ulceration or gangrene. Malone
and colleagues16 conducted a retrospective study of 568 PAD patients admitted to
Australian hospitals. They found that 51.4% of the admitted patients had PAD
without diabetes and 48.6% of admitted PAD patients also had diabetes. PAD
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patients with concomitant diabetes had a greater average length of stay in the
hospital by five days and incurred expenses almost $2000 more per inpatient
episode than PAD patients without diabetes16.
PAD patients have variable physical symptoms, including pain and
ulceration, but the effects of PAD are more profound than leg symptoms. PAD is
associated with decreased mobility and physical functioning. Pain and decreased
physical functioning have been shown to negatively impact quality of life in PAD
patients. In one study, health-related quality of life was lower for PAD patients with
intermittent claudication compared to age- and gender-matched controls at
baseline, but similar to controls following a 12-month intervention designed to treat
the disease18. Another study showed that PAD patients report lower quality of life
compared to both control participants and people with coronary artery disease19.
Furthermore, the risk of mortality from cardiovascular disease and all-cause
mortality is increased in PAD patients20-22. Due to the profound impact that PAD has
on quality of life and mortality, it is important to accurately diagnose and develop
therapies to treat this debilitating disease.
The ankle-brachial index (ABI) is an objective and noninvasive measure used
to clinically diagnose PAD. Patients with an ABI of 1.0 to 1.4 are considered to have
no blockage or narrowing of the arteries in the leg. An ABI of less than 0.9 is
diagnostic of PAD23. As ABI decreases below 0.7, the severity of the blockages and
PAD symptoms increases. The classic symptom of early PAD is intermittent
claudication, or pain upon exertion caused by inadequate blood being supplied to
the leg muscles. Intermittent claudication may be present in mild to moderate
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disease. As PAD progresses, pain at rest develops, and this stage of the disease is
called critical limb ischemia. Not all patients with PAD experience the classical
manifestations of the disease24, 25. Many PAD patients have atypical leg pain; and per
data from NHANES, as many as two-thirds of adults over the age of 40 years are
asymptomatic23, 26. Due to the high rates of PAD in diabetic patients and the blunted
PAD symptomology in diabetic patients, simple diagnostic tools, such as ABI, should
be more frequently employed to test for PAD in diabetics and other at-risk people.
Peripheral artery disease, whether symptomatic or asymptomatic, has
negative effects on lower-extremity function. In one study, disease severity, which
was measured by ABI, was related to decreased performance on a 6-minute walk
test, a standing balance test, and a 4-meter walking velocity test27. Another study
assessed physical functioning of PAD patients and observed that patients with a low
ABI at baseline showed the greatest functional declines at a two-year follow-up
compared to patients with less severe PAD and control participants without PAD28.
Importantly, even patients with asymptomatic PAD experienced greater functional
declines than control patients over a two-year period28. Furthermore, PAD patients
with diabetes have poorer lower extremity physical function than PAD patients
without diabetes29.
Patients with PAD also have impaired endothelial function, which is an
important component of vascular health. Flow mediated dilation (FMD) is a key
measure of endothelial function, and FMD is clinical tool that may predict the risk of
future cardiovascular events. Varela et al.30 utilized brachial artery FMD to assess
endothelial function in PAD patients, and they demonstrated impaired endothelium-
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dependent dilation in PAD patients compared to controls30. Several other studies
have also shown that the FMD response is decreased in PAD patients when
compared to younger healthy controls31 as well as older, age-matched controls32,
which highlights the pathological endothelial function and increased risk of future
cardiovascular events in PAD patients.

Pathophysiology of PAD
In PAD, there are periods of tissue ischemia, especially during exertion. The
periods of ischemia are followed by periods of reperfusion. The repeated cycle of
ischemia and reperfusion causes cellular damage in PAD patients, known as
ischemia reperfusion injury (IRI). IRI induces biochemical changes in both the local
tissue environment and systemic circulation, including production of reactive
oxygen species (ROS), activation of circulating immune cells33, and release of
proinflammatory cytokines and chemokines34. The oxidative stress and
inflammatory processes in PAD are central to the pathogenesis of the disease.
Furthermore, they contribute to muscular dysfunction and progression of
atherosclerosis in PAD patients.
Oxidative Stress
Patients with PAD show increased markers of oxidative stress. The majority
of ROS in the human body are produced by the mitochondria at complex I and
complex III of the electron transport chain, and ROS production is increased at
complexes I and III when they are damaged. Pipinos et al.35 showed mitochondrial
defects in PAD patients at complexes I and III, indicating that PAD patients may
8

generate greater ROS than healthy controls. In addition to oxidative stress produced
by the mitochondria, neutrophils and endothelial xanthine oxidase have also been
shown to be a source of ROS in PAD patients36, 37. In line with greater oxidant stress,
PAD patients also display decreased antioxidant defenses, as demonstrated through
decreased hydroxyl radical antioxidant capacity in the sera of people with PAD38.
Pipinos et al.35 also assessed antioxidant capacity in PAD patients, and they
observed decreased activity of mitochondrial superoxide dismutase in the skeletal
muscle of PAD patients. This imbalance between oxidants and antioxidants may be
the reason that PAD patients display greater overall oxidative damage35.
Oxidative damage is assessed by measuring cellular function and quantifying
the end products of ROS-induced damage. In PAD, oxidative stress has been
implicated in vascular endothelial injury, which has been demonstrated through
increased endothelial cell apoptosis38 and altered arterial elasticity39. Kals et al.39
performed a non-invasive in vivo assessment of arterial elasticity using pulse wave
analysis to quantify the elasticity of large and smaller arteries in PAD patients. They
also assessed the oxidative stress of PAD patients and control participants by
measuring a marker of lipid peroxidation called 8-iso-prostaglandin F2alpha39. They
observed a significant correlation between increased oxidative stress and decreased
arterial elasticity in PAD patients, but not in the control group; therefore,
establishing a link between oxidative stress and endothelial damage39. Hickman et
al.40 observed increased thrombomodulin, a marker of endothelial damage, in PAD
patients compared to healthy control participants. Vascular endothelial damage is
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clinically relevant because it contributes to atherosclerosis and the risk for
thrombotic events.
Oxidative damage has also been observed in the skeletal muscle of patients
with PAD where markers of oxidative damage, including protein carbonyls, lipid
hydroperoxides, and 4-hydroxy-2-nonenal (HNE) levels were greater in the
gastrocnemius of PAD patients compared to control patients35. Weiss and
colleagues41 observed 30-40% greater oxidative damage in myofibers of PAD
patients compared to controls. Further, oxidative damage to muscle fibers was
related to disease severity and blood flow limitation41. Importantly, cellular damage
associated with oxidative stress is known to cause inflammation42.
Inflammation
Inflammation is the immune system’s response to damage in order to restore
tissue homeostasis. Inflammation must be properly regulated to ensure tissue
repair because unchecked inflammation leads to collateral damage and disease43.
Inflammatory processes are triggered in response to oxidative damage; and
inflammation is involved in the initiation, progression, and amplification of
atherosclerosis. Atherosclerotic plaques in peripheral arteries are a major factor in
the development of PAD.
PAD is an inflammatory disease. Gardner and colleagues38 showed that PAD
patients had a greater concentration of circulating markers of inflammation,
including C-reactive protein (CRP) and interleukin-8 (IL-8) compared to control
patients. PAD patients with intermittent claudication showed greater circulating
concentrations of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)
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compared to controls at baseline and following an exercise test44. While many
signaling pathways lead to inflammation, NF-κB is a key inflammatory regulator
with known roles in the development and progression of atherosclerotic disease.
Importantly, TNF-α is a known stimulator of NF-κB, and both IL-6 and IL-8 gene
expression is regulated by NF-κB. Therefore, NF-κB activation may have a role in the
pathogenesis of PAD. It may be important to elucidate the role of the NF-κB-related
inflammatory processes in the pathogenesis of PAD in order to develop effective
therapies for the disease.
There are several basic steps involved in atherosclerotic plaque formation,
each of which involves inflammation. An early step in the atherosclerotic process is
the activation and increased permeability of endothelial cells, which allows for LDL
to transmigrate into the intima45. Endothelial cell activation occurs via
proinflammatory mediators, such as TNF-α45. PAD patients have been shown to
have greater concentrations of circulating TNF-α compared to controls44. TNF-α
induces endothelial cell expression of the adhesion molecules E-selectin and Pselectin45. The selectins tether leukocytes to the endothelium46. PAD patients have
been shown to have greater circulating levels of these selectins compared to
controls44.
Once leukocytes are tethered to endothelial cells, they become activated and
exert effects at the site of the forming atherosclerotic lesion. Leukocyte activation
occurs via chemokines secreted from endothelial cells, including MCP-1 and IL-845.
Activated leukocytes then trigger further endothelial cell expression of adhesion
molecules intracellular adhesion molecule-1 (ICAM-1) and vascular cellular
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adhesion molecule-1 (VCAM-1) leading to eventual transmigration of leukocytes
into the vessel wall and surrounding tissue45. NF-κB is involved in the upregulation
of these adhesion molecules on endothelial cells as it is known to regulate VCAM-1
gene expression47. Animal studies have shown that VCAM-1 is expressed on
endothelial cells during early atherosclerotic lesions, and then VCAM-1 expression
predominates in intimal cells as the lesion progresses48. Once leukocytes have
adhered to the lesion, they enter the vessel wall with the help of other cytokines,
including MCP-1. In addition to being chemoattractant for monocytes that will
participate in the atherosclerotic process, MCP-1 also stimulates leukocytes to form
strong adhesions through VCAM-1; therefore, making MCP-1 a key cytokine
involved in the progression of atherosclerosis. Both animal and human models
demonstrate that MCP-1 is highly expressed in atherosclerotic lesions. Furthermore,
knockout studies using mice deficient in MCP-1 or its receptor, CCR2, show that this
NF-κB regulated cytokine is necessary for atherosclerotic plaque development49, 50.
Atherosclerosis is harmful not only because it disrupts blood flow leading to tissue
ischemia, but also because atherosclerotic plaques can rupture leading to stroke or
myocardial infarction.

Impact of PAD on Muscle Function
Skeletal muscle damage is an important component of the pathogenesis of
PAD, as it may influence the inflammatory signaling environment and affect vascular
remodeling. Light and electron microscopy has been used to show skeletal muscle
myopathy in PAD patients. PAD patients show evidence of skeletal muscle necrosis,
12

phagocytosis, central nuclei, and fibrosis51, 52. Furthermore, ultrastructural changes
to the skeletal muscle of PAD patients with intermittent claudication include
sarcomere changes and Z-line disorganization52. Beyond histological evidence of
muscle changes in PAD patients, several studies point to an intrinsic muscle
myopathy as a contributing factor to decreased physical functioning in PAD patients.
Two separate studies that treated PAD patients with bypass surgery found that
blood flow restoration did not fully restore physical function, thus showing that
even adequately perfused muscles show functional deficits53, 54. These studies
suggest that muscle pathologies may contribute to the physical limitations in PAD
patients53, 54. McDermott and colleagues55 have provided additional evidence for an
intrinsic muscle dysfunction independent of hemodynamics. They tested the lower
extremity strength of community-dwelling older adults using a 5-second maximal
isometric contraction, which is a blood flow independent test55. They found that
participants with PAD had lower strength than control participants55; therefore,
they concluded that muscular dysfunction may occur independent of blood flow
limitations.
PAD has been shown to affect skeletal muscle mitochondria. Evidence for
mitochondrial dysfunction has been demonstrated in many studies, as reviewed by
Pipinos and colleagues56. The first studies to implicate mitochondrial dysfunction as
part of the pathophysiology of PAD showed that PAD patients have approximately
40% to 60% lower peak VO2 consumption during maximal exercise compared to
healthy controls57-59; and more importantly, PAD patients do not increase oxygen
consumption at the onset of exercise as quickly as healthy controls60, 61, thus
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indicating a metabolic deficiency. Further, Bauer and colleagues61 showed that
hemoglobin desaturation lagged at the onset of exercise compared to hemoglobin
desaturation in control participants; thus, indicating that oxygen utilization by
mitochondria may be defective. Further, histomorphological analysis of
mitochondria revealed hypertrophy, hypercristae, lipid vacuolization, and
ultrastructural abnormalities in skeletal muscle mitochondria of PAD patients. Thus,
mitochondrial dysfunction may contribute to the skeletal muscle myopathy that
limits physical functioning in PAD patients56, 62.

Medical Treatment for PAD
Interventions for treating PAD include both pharmacotherapy and exercise.
Two groups have published guidelines for the treatment of PAD: the American
College of Cardiology (ACC)/American Heart Association (AHA)13, 63 and the TransAtlantic Inter-Society Consensus II (TASC II)64. Recommendations include using
pharmaceuticals to treat concomitant disease, such as hypertension or dyslipidemia,
and prevent stroke or myocardial infarction with acetylsalicylic acid64. Cilostazol, a
phosphodiesterase III inhibitor, is the most promising pharmacological treatment
option for intermittent claudication patients; and the drug has shown success in
improving treadmill walk performance, but is not as effective as supervised exercise
or surgical revascularization64. If PAD is severe and loss of limb is threatened,
surgical interventions are performed to attempt restoration of adequate blood flow.
However, due to concomitant disease, many patients are unable to undergo surgical
procedures. These patients are prescribed pharmaceuticals and exercise. Both the
14

ACC/AHA and TASC-II recommend exercise for PAD patients13, 64. Recommendations
for exercise include walking until a moderate to high level of claudication pain is
experienced followed by rest and repeating as often as possible13, 64. Dynamic and
static leg exercises are also recommended13. Exercise has been shown to be effective
at reducing PAD symptoms65, 66 and reducing risk factors for other atherosclerotic
diseases in PAD patients67. Unfortunately, PAD patients show poor adherence to
exercise programs68. They describe a fear of falling, leg pain upon walking, and
needing to rest due to leg pain as barriers to participating in physical activity69. A
lack of physical activity feeds into a cycle of symptom exacerbation and increased
aversion to exercise. Effective therapies that are designed to restore adequate blood
flow to ischemic muscles, such as stem cell therapies, may show better adherence
and increased efficacy for PAD patients than currently availably therapeutic options.

Clinical Trials Using Stem Cell Therapies for PAD Treatment
The goal of stem cell therapies for the treatment of PAD is to increase
vascular remodeling of the ischemic limbs in order to restore adequate blood flow
and alleviate symptoms. In 2002, Tateishi-Yuyama et al. published a pilot study
demonstrating the feasibility and potential therapeutic benefit of injecting
autologous bone marrow derived mononuclear cells into ischemic limbs of people
with PAD70. Since that initial pilot study, clinical trials have progressed, and a 2015
meta-analysis reported that stem cell therapy may improve ulcer healing,
amputation, and ABI compared to control treatments, but that stem cell therapy did
not improve risk of all-cause mortality71. Therefore, stem cell therapy may be
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beneficial in the short term, but many unanswered questions about how to engineer
a safe, effective, and long-term stem cell therapy remain.
A limited number of clinical trials that have demonstrated safety and
therapeutic efficacy of PAD stem cell therapies. The inconsistent demonstration of
efficacy is likely due to the variability of stem cell treatments that were investigated.
Clinical trials differ in the source of stem cell being investigated. Stem cells
harvested from the recipient and injected back into the recipient are called
autologous transplantations. Autologous stem cell transplantations are often
utilized due to decreased risk of rejection following transplantation. Fadini72 et al.
used meta-analysis to show that autologous stem cell transplantation is safe and can
be effective to treat PAD. However, this method may be limited by cell availability.
Furthermore, autologous stem cells from a patient with PAD may have intrinsic
dysfunctions that limit their therapeutic potential. In contrast to autologous
therapies, some studies investigate allogeneic transplantations73, or
transplantations of human cells into a different person. Gupta and colleagues73
showed that allogeneic cell transplantation improved resting pain scores and ankle
brachial pressure index compared to placebo in a phase I/II clinical trial. Allogeneic
transplantations run the risk of host rejection, but this form of therapy may provide
the benefit of transplanting “healthy” donor cells into a PAD patient.
The type of stem cell that is transplanted also varies across studies. The most
common sources of stem cells include bone marrow mononuclear cells, peripheral
blood mononuclear cells, skin cells, and adipose-derived stem cells (reviewed in
Gupta et al.74). Even within these tissues, there is variability between the subtypes of
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bone marrow mononuclear cells or adipose derived cells. Transplantation protocols
in clinical trials can also vary by the number of cells transplanted, the frequency of
transplantations, and the site of transplantation74, 75. Due to the many sources of
variability and a lack of consistency in stem cell transplantation protocols, clinical
trials investigating a stem cell therapy for the treatment of PAD are still in their
infancy. As the prevalence of PAD continues to rise worldwide, there is a pressing
need for effective stem cell therapies to alleviate the pain of PAD by promoting the
revascularization of ischemic tissues.

Mechanisms of vascular remodeling
To alleviate symptoms and restore functionality of muscles, PAD therapies
should be designed to restore blood flow to tissues. The restoration of blood flow
can occur through several vascular remodeling processes, including angiogenesis,
and arteriogenesis. Angiogenesis and arteriogenesis are vascular remodeling
processes that could be targeted by a stem cell therapy. Angiogenesis and
arteriogenesis require the coordination among a variety of cell types, including
skeletal muscle pericytes, a novel stem cell candidate for PAD therapy. While
inflammation is key in the pathogenesis of PAD, it is also an important component of
the revascularization process. It is important to understand the mechanisms of
vascular remodeling, including the cells that contribute to remodeling. By
elucidating the mechanism by which cells contribute to revascularization, cellular
therapies can be devised that harness stem cells’ ability to contribute to
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revascularization in the face of inflammation associated with concomitant disease,
such as T2DM.

Angiogenesis
Angiogenesis is a vascular remodeling process whereby new blood vessels
are created from existing vessels. The main stimulus for angiogenesis is hypoxia76.
In the initial stages of PAD, hypoxia stimulates adaptive-angiogenesis, which
activates hypoxia-inducible factor-1α (HIF-1α). HIF-1α is a transcription factor that
regulates vascular endothelial growth factor (VEGF) gene expression and other
genes that influence capillary sprouting77. VEGF and other angiogenic cytokines act
on the endothelium to cause proliferation of resident endothelial cells, recruitment
of endothelial progenitor cells, or differentiation of resident cells to form new
capillaries78, 79. Endothelial cell differentiation produces several cell types that
contribute to the nascent vessel: tip, stalk, and tube cells80. The tip cells influence
the direction of vessel growth. The stalk cells are proliferative and form the trunk of
the nascent vessel. The tube cells form the lumen of the new vessel. Finally
perivascular cells couple with the endothelial cells and support the nascent
capillary81. Newly formed capillaries have a 8-12 µm diameter, and they act to
increase blood flow to the ischemic tissue82.
PAD patients may have capillary rarefaction and impaired angiogenic
processes. Patients with PAD show decreased capillary density in the skeletal
muscle compared to control participants83, 84. The inflammatory nature of PAD may
negatively affect angiogenesis in this patient population. The role of inflammation in
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angiogenesis may be both cell type and context specific85, 86. Several studies have
suggested that inflammation mediated by endothelial cell NF-κB activation may be
angiostatic by regulating endothelial cell migration, proliferation, and/or survival,
as reviewed by Taburyn and Griffioen85. Evidence to support the notion that
endothelial cell NF-κB activation may be angiostatic was provided by Kisseleva et
al.87 showing that transgenic mice with a loss of endothelial cell NF-κB activation
demonstrated enhanced angiogenesis. Furthermore, studies have also shown that
endothelial cell NF-κB activation decreased extracellular matrix degradation,
thereby preventing angiogenesis88. However, the majority of studies suggest that
inflammation mediated by NF-κB activation in the endothelium enhanced
angiogenesis by preventing apoptosis89 and enhancing cell proliferation86.
Endothelial cell NF-κB activation was shown to promote angiogenesis by positively
regulating endothelial cell integrity and vascular homeostasis in a zebrafish model90.
In vitro studies also support a role for endothelial cell NF-κB in promoting
angiogenesis91. Shono et al.91 observed that ROS enhanced endothelial cell tube
formation in vitro due to NF-κB activation. While inflammation may promote
angiogenesis in some contexts, the pathological inflammatory environment
characteristic of PAD and also diabetes impairs angiogenic processes.
Angiogenic processes are impaired in diabetic patients with limb ischemia92.
The mechanisms for diabetic impairment of angiogenesis include dysfunctional
angiogenic signals via decreased HIF-1α levels93. Dysfunctional hypoxia signaling
can lead to dysfunction of the normally proangiogenic vascular endothelial growth
factor (VEGF) pathway94. Downstream of VEGF signaling, the angiogenic
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phosphoinositide 3′ kinase/AKT/ endothelial nitric oxide synthase (eNOS) pathway
is disrupted92. Furthermore, diabetes induced oxidant stress negatively impacts
nitric oxide (NO) signaling, which impairs vascular remodeling in ischemic disease95,
96.

In additional to pathologic angiogenic signals, the diabetic environment triggers

anti-angiogenic signals due to increased inflammation, oxidative stress, and
signaling from advanced glycation end products (AGEs)92. Furthermore, cells that
support angiogenesis, including bone marrow progenitor cells and monocytes, are
negatively affected by diabetes92. Studies have shown that T2DM decreases
endothelial progenitor cell numbers97, 98, alters recruitment of angiogenic cells to
the site of ischemic damage99, and also impairs the function of angiogenic cells10, 100.

Arteriogenesis
Under physiological conditions, collateral vessels connect vascular beds and
form networks to distribute blood flow based on demand, for example when one
muscle group is contracting more than another muscle group. In humans, collateral
arteries are 20-100 μm in diameter, thus having greater capacity for blood flow than
the capillaries that are formed through angiogenesis. The main stimuli for altering
collateral vessel diameter are shear stress and inflammation101. Acute changes in
blood flow and pressure alter the shear stress in collateral vessels, and this leads to
transient vasodilation of collateral vessels. Collateral artery vasodilation is
predominantly mediated by NO. This vasodilation is an acute response that leads to
increased perfusion of distal tissues.
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Chronic stressors activate the endothelium to undergo permanent
remodeling of the arterial wall via growth and expansion of the collateral vessels,
termed arteriogenesis102. Just as inflammation is important in angiogenesis,
inflammatory signaling is also an important component of the arteriogenic process.
The cytokine monocyte chemoattractant-1 (MCP-1) is an inflammatory cytokine
that is considered to be the most potent of the arteriogenic stimuli102. MCP-1 is
upregulated by the endothelium in response to shear stress103. This is followed by
monocyte chemotaxis and secretion of growth factors, including fibroblast growth
factors (FGFs) and further MCP-1, to promote endothelial cell and smooth muscle
cell proliferation during arteriogenesis. Hoefer and colleagues104 showed that
intravenous injection of MCP-1 caused both monocyte and granulocyte
chemoattraction and enhanced arteriogenesis following hindlimb ischemia in
rabbits. In addition to inflammatory signals, NO and progenitor cells mediate the
arteriogenic remodeling process. Aicher et al.105 demonstrated the essential role for
NO in mediating arteriogenesis via recruitment of supporting cells. Progenitor cells,
including endothelial progenitor cells, are one such supporting cell type that is
critical for arteriogenesis79, 106, 107. Progenitor cells support the remodeling
collaterals through paracrine interactions with resident cells and migrating
leukocytes, and some evidence exists to suggest that progenitor cells may also
incorporate into the remodeling vasculature during arteriogenesis107, 108. Under
physiological conditions, NO, inflammation, and progenitor cells mediate
arteriogenesis that increases overall conductance across the vascular bed; however,
disease states can disrupt the arteriogenic process.
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Pathological conditions, such as PAD and T2DM, are characterized by
aberrant inflammation and oxidative stress, which leads to pathological arterial
remodeling109, 110. Belin de Chantemele et al.111 showed that chronic flow mediated
arterial enlargement is impaired in diabetic rats compared to rats without diabetes.
It is hypothesized that AGEs, which are present in T2DM, impair the remodeling
process by interfering with the ability of matrix metalloproteinases (MMPs) to
disrupt the extracellular matrix112, 113. Furthermore, MCP-1 signal transduction may
be altered in diabetics with PAD. MCP-1 is upregulated in patients with T2DM114, but
that signal may not be effectively transduced by endothelial and bone marrow
progenitor cells to augment arteriogenesis110. The mechanisms by which diabetes
affects progenitor cell function during arteriogenesis are not fully known.
Understanding these mechanisms may inform future cell therapies aimed at
increasing arteriogenesis in PAD patients with diabetes.
There is clear evidence that inflammation is altered in diabetes, and that this
altered inflammation negatively impacts vascular remodeling, both angiogenesis
and arteriogenesis, in response to ischemia. Potential stem or progenitor cell
therapies must overcome the inhibitory signals that prevent vascular remodeling.
One such cell type, known as pericytes, is a novel candidate for PAD therapy, and
pericytes may be useful to promote revascularization of ischemic tissues in PAD.

Role of Pericytes in Vascular Remodeling
Pericytes are multipotent mesenchymal-like stem cells that reside under the
basement membrane of the microvasculature115. They are found in varying densities
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ubiquitously throughout the microvascular. They reside in the perivascular space
surrounding capillaries, precapillary arterioles, and postcapillary venules at varying
densities ranging from a 1:1 ratio of pericytes to endothelial cells in places such as
the retina and the blood-brain barrier, to a less dense 1:10-1:100 in the skeletal
muscle116, 117.
Pericytes have a wide range of functions, depending on their anatomical
location. In general, pericytes are known to regulate vessel tone and maintain
vascular homeostasis115. Pericytes respond to stimuli from the local tissue
environment. Notably, pericytes respond to muscle damage through both
differentiation6 and paracrine signaling118, 119 mechanisms. Sassoli et al.118 provide
evidence for the in vitro paracrine signaling abilities of pericytes co-cultured with
skeletal muscle cells. They showed that conditioned medium from mesenchymal
stem cells, which share many characteristics with pericytes, enhanced skeletal
muscle myoblast proliferation. In vivo, Hyldahl et al.120 showed that pericytes
respond to skeletal muscle damage in vivo by activating inflammatory signaling
pathways; and a follow-up study showed that pericyte NF-κB activation may
enhance endothelial cell proliferation via paracrine mechanisms in vitro121.
Furthermore, Chen and colleagues119 attributed improvements in markers of
angiogenesis and cardiac function in ischemic heart disease to the paracrine effects
of pericytes, although pericyte engraftment into cardiac cells was observed to a
minimal extent. Overall, it is suspected that skeletal muscle pericytes respond to
ischemic injury via paracrine and differentiation mechanisms to promote
angiogenesis and arteriogenesis in patients with PAD.
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Pericytes are necessary for physiological angiogenesis during development
and throughout adult life during wound healing, reproductive cycling, and
inflammation. In the initial stages of angiogenesis, pericytes shorten their processes,
hypertrophy, increase DNA synthesis, and proliferate122. Nehls and colleagues123
observed pericytes at the leading edge of sprouting capillaries in an in situ model of
angiogenesis. Furthermore, they observed pericytes within the gaps between
endothelial sprouts that were presumably about to merge, suggesting that pericytes
may guide vessel development123. Additionally, pericytes are known to stabilize the
microvasculature124, and a failure to recruit PDGFRβ-positive pericytes to the
developing vasculature leads to vascular instability and regression125. Finally,
pericytes have a role in vessel stabilization through regulating basement membrane
matrix deposition126. Taken together, there is strong evidence showing the necessity
of functional pericytes in angiogenesis. A stem cell therapy that utilizes the
angiogenic potential of pericytes to enhance perfusion in ischemic limbs could be a
promising PAD therapy.
Few studies have examined the role of pericytes in arteriogenesis. Huntsman
et al.127 used a mouse model of skeletal muscle damage to show that pericytes
contribute to arteriogenesis potentially by secreting paracrine factors, including
basic fibroblast growth factor (bFGF), which has been shown to enhance
arteriogenesis. Furthermore, they showed that pericytes secrete inflammatory
arteriogenic factors, including granulocyte macrophage colony stimulating factor
(GM-CSF)127. While this is not a direct model of PAD, their model does involve
skeletal muscle damage, which is also present in PAD. Furthermore, data from our
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lab shows that pericytes in an in vitro model of skeletal muscle injury secrete GMCSF121, as well as the arteriogenic factor, MCP-1, although arteriogenesis was not
assessed.
Diabetes may hinder pericyte-mediated vascular remodeling in PAD. Type 2
diabetes, like PAD, is an inflammatory disease128, and inflammation may hinder the
ability of pericytes to aid in vascular remodeling. Vono and colleagues129 recently
showed that skeletal muscle pericytes from diabetic patients with critical limb
ischemia are dysfunctional compared to cells derived from patients without
diabetes. Specifically, they demonstrated decreased in vitro differentiation capacity
and reduced ability to support endothelial tube formation in skeletal muscle
pericytes isolated from diabetic patients compared to patients without diabetes.
This in vitro data suggests that pericytes may also be impaired in their ability to
support endothelial cells, promote angiogenesis, and differentiate in vivo in diabetic
patients. Limited data exists on the effects of PAD specifically on pericyte function in
ischemic skeletal muscle; however, studies of pericyte dysfunction in diabetic
retinopathy are well documented130. In one study, Romeo and colleagues131 showed
that retinal pericytes from diabetic eye donors had increased NF-κB activation
compared to controls; and furthermore, they showed that there was increased
apoptosis of cells in vessels surrounded by NF-κB-positive pericytes. To devise
effective stem cell therapies, potential cell candidates for the treatment of PAD
should be thoroughly examined in a physiologically relevant disease model that
includes concomitant diseases, like T2DM.
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Pericyte cell therapy for PAD
Due to pericytes known roles in vascular remodeling, pericytes may be an
optimal target for the development of a cellular therapy to revascularize ischemic
tissues. While many different types of cells may aid in revascularization of ischemic
limbs, pericytes are a unique cell type that has specific advantages over other cell
types. First, pericytes are tissue-resident stem cells. They reside in the perivascular
space throughout the microvasculature, putting them in the prime position to
respond to ischemic insults. Furthermore, pericytes are multipotent progenitors 117.
Like MSCs, they have been shown to differentiate into mesenchymal lineages and
transdifferentiate into endothelial cells 3, 7, 9, which is a potential cellular mechanism
by which they may restore blood flow to injured tissue. Through their
transdifferentiation functionality, as well as their paracrine roles in vessel
stabilization and angiogenesis 3, 4, pericytes may aid in the adaptive vascular
remodeling processes of angiogenesis and arteriogenesis during postischemic
neovascularization. However, pericytes may be negatively affected by inflammatory
disease, such as diabetes, which may negatively impact their therapeutic potential
for PAD treatment.
To investigate the potential efficacy of a stem cell therapy to treat peripheral
artery disease, a murine hindlimb ischemia model is used. Murine hindlimb
ischemia models are used to study the effect of cell therapy on postischemic
neovascularization. To increase the clinical translatability of the murine hindlimb
ischemia model, T2DM mice should be utilized.
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Mouse Model of Peripheral Artery Disease
Hindlimb Ischemia Model
Peripheral artery disease is experimentally induced in animal models using a
femoral artery ligation to produce limb ischemia. In most models of limb ischemia,
the surgery is performed unilaterally so that the contralateral limb can serve as a
control. The hindlimb ischemia model has been evaluated in many small animals,
including rodents, rabbits, and pigs; however, mice are commonly utilized due to
low cost and greater ability to use transgenic lines. Femoral artery ligation surgery
is the procedure that is utilized to induce the acute ischemia in the hindlimb of
animals. For this procedure, an incision is made in the hindlimb, and the femoral
artery is dissected away from the femoral nerve and vein. Ligatures are tied around
the femoral artery and its branches from the inguinal ligament to the saphenouspopliteal bifurcation, and then the femoral artery is excised. Following excision of
the artery, the incision is closed and animals recover132. The surgical procedure
described induces an acute, severe decrease of blood flow that is used to model
critical limb ischemia. It is also possible to model progressive and less severe PAD
using small animals133. A limitation of the hindlimb ischemia model, whether acute
or progressive, is that it does not mimic the atherosclerosis that is seen in most
human PAD patients. Still, this model has proven useful as a preclinical model for
PAD therapy75.
Laser Doppler Perfusion Imaging (LDPI) is used to assess blood flow in the
experimental and control limbs following the induction of hindlimb ischemia. Using
LDPI, laser light applied to the skin creates a Doppler shift signal due to the
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movement of red blood cells. The signal generated is a surrogate for perfusion. LDPI
is a useful technique because it provides reproducible results in real-time.
Furthermore, this non-invasive tool allows for the detection of microvascular
changes, as well as the collection of longitudinal data134. The disadvantages of this
technique include motion artifact noise and varying perfusion signals based on
tissue properties134.
Mice
C57BL/6 mice are commonly used in hindlimb ischemia models134. This
strain typically demonstrates a more complete recovery of limb perfusion compared
to other commonly used strains, such as BALB/c mice, due to greater collateral
networks and collateral artery recruitment in response to ischemia. While older
mice are relevant to human disease, mice at approximately 3 months of age are
typically used to study revascularization in this model. By 3 months, mice have
slowed growth rates; therefore, mitigating growth as a confounding factor.
Additionally, the younger mice show higher rates of survival, better functional
recovery, and more robust remodeling responses than older mice. Finally, younger
mice are associated with lower research costs. However, a disadvantage of young
mice is that they typically do not have the comorbidities that accompany human
disease, such as hypertension and diabetes; however, these conditions can be
experimentally induced in young mice.
The leptin receptor-deficient db/db mouse is a commonly used strain in the
study of T2DM. Leptin is a hormone that is primarily produced by adipose tissue. It
binds to leptin receptors in the central nervous system that control satiety and
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appetite behaviors. Db/db mice lack a functional leptin receptor, which leads to
obesity, hyperglycemia, hyperinsulinemia, and ultimately, T2DM135. Hindlimb
ischemia can be induced in db/db mice to model PAD in animals with diabetes.
Inducing limb ischemia in db/db mice may be more physiologically relevant to PAD
than inducing limb ischemia in wild type mice, as T2DM is a strong predictor for the
development of PAD.
Response to hindlimb ischemia
Acute hindlimb ischemia results in dramatically decreased blood flow of less
than 20% relative to the control limb. Limb ischemia stimulates a
neovascularization response that progresses over the course of 40 days. The initial
seven days of blood flow recovery is the result of collateral artery vasodilation,
which is predominantly a NO mediated response. During the first 10-14 days postsurgery in wild type mice, blood flow increases to about 60% of the control limb.
Beyond the first 14 days of recovery, vascular remodeling, including arteriogenesis
and angiogenesis, takes place and blood flow recovery continues to slowly improve
to a maximum recovery of approximately 70% at 40 days after surgery for wild type
mice136. Db/db mice have impaired vasodilation and vascular remodeling in
response to limb ischemia such that they recover only approximately 30-40% of
their blood flow relative to the contralateral control limb10.
The dramatic ischemia induced by femoral artery ligation in the thigh region
affects distal skeletal muscles and stimulates a regenerative response. Hindlimb
ischemia has been shown to cause atrophy in the tibialis anterior that does not
recover by 40 days post-surgery136. In the gastrocnemius, atrophy is observed 2
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weeks post-surgery, but muscle mass is not different from controls at 40 days postsurgery136. Studies have also shown evidence of necrosis occurring in the tibialis
anterior137. This model provides a tool to assess the effects of stem cell therapy on
the skeletal muscle.
Induction of hindlimb ischemia via femoral artery ligation causes
inflammation and vascular remodeling136. Scholz et al.138 examined the time course
of vessel remodeling in C57BL/6 mice following experimentally induced hindlimb
ischemia. They observed activation of endothelial cells and evidence of cellular
proliferation at 3 days post-induction of hindlimb ischemia138. They also utilized
angiograms to assess arteriogenesis, and they observed significant enlargement of
pre-existing collaterals138. Collateral vessel diameter increased from 35.7±2.6 μm at
baseline to 84.8±5.4 μm at 21 days. Furthermore, collateral vessel wall area
increased from 553±69 μm2 to 1601±127 μm2 at the 21 day time point. Capillary
density was also shown to increase in the C57BL/6 mice at 21 days post-surgery138.
This model provides a tool to assess the ability of stem cell therapies to increase
vascular remodeling.

Pericyte Mediated Neovascularization
To date, few studies have examined the ability of skeletal muscle derived
pericytes to augment postischemic neovascularization in a murine model of limb
ischemia. The results of several studies that have investigated cells similar to
skeletal muscle pericytes indicate that skeletal muscle pericytes may be able to
improve postischemic neovascularization139-141. Birbrair and colleagues140
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demonstrated that transplanted skeletal muscle pericytes improved limb
revascularization assessed via MRI angiography following femoral artery ligation in
a single, early time point (10 days) after the induction of ischemia. Further, Dar et
al.139 assessed the ability of intramuscularly transplanted pluripotent stem cell
(iPSC)-derived pericytes to show enhanced blood flow recovery up to 28 days postinduction of limb ischemia. Importantly, they provided evidence that iPSC-derived
pericytes incorporated into both the muscle and vasculature139. Finally, Gubernator
et al.141 showed that intramuscularly transplanted saphenous vein adventitial
progenitor cells, a cell type similar to pericytes, improved neovascularization in vivo
in mice. While these three studies provide evidence for the therapeutic potential of
pericytes, they either did not assess postischemic neovascularization over a
complete time course or they did not utilize muscle resident pericytes. Furthermore,
the aforementioned studies failed to assess postischemic neovascularization in a
T2DM model of PAD as the diabetic environment may affect the therapeutic
potential of pericytes.

The Effect of Type 2 Diabetes on Pericyte Mediated Neovascularization
Stem cell therapies appear to be less effective in diabetic environments10, 142.
Diabetes is strongly associated with an elevated risk of PAD, and PAD is more severe
in diabetic patients. Therefore, it is essential to evaluate potential PAD therapies
under diabetic conditions. None of the studies on pericyte transplantation cited
above139-141 assessed postischemic neovascularization in a T2DM model of PAD.
However, work from Yan and colleagues10 demonstrates that the diabetic
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environment negatively impacts the therapeutic potential of bone marrow MSCs, a
cell type that shares similarities with skeletal muscle resident pericytes10, 143, 144. Yan
et al.10 used a hindlimb ischemia model of PAD to show that bone marrow-derived
MSCs isolated from T2DM mice have an impaired ability to support
neovascularization compared to MSCs isolated from wild type mice. Furthermore,
MSCs from diabetic donors favored adipocyte differentiation compared to
endothelial cell differentiation in vivo; and oxidative stress was implicated as a cause
of this dysfunction10. Endothelial cell differentiation may be critical for angiogenesis
and arteriogenesis during postischemic neovascularization whereas adipocyte
accumulation in ischemic tissues may impair effective blood flow recovery. Evidence
from Vono et al.129 also provides support for stem cell dysfunction in diabetes due to
activated pro-oxidative pathways. They showed that skeletal muscle pericytes
isolated from humans with diabetic PAD showed impaired differentiation and
impaired ability to support endothelial cell tube formation in vitro. Finally, Caporali
and colleagues145 demonstrated impaired neovascularization following limb
ischemia in diabetic mice due to inflammation in endothelial cells that negatively
impacted crosstalk with skeletal muscle pericytes145. In summary, inflammation and
oxidative stress associated with T2DM negatively affects the ability of stem cells to
augment postischemic neovascularization. It is hypothesized that the diabetic
environment may impair the ability of skeletal muscle pericytes to augment
postischemic neovascularization in a T2DM model of PAD.
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Conclusion
PAD is an increasing public health concern, and evaluating candidate
therapies to restore blood flow are critical for the treatment of this debilitating
disease. Supporting evidence from recently published studies provides proof of
concept that skeletal muscle pericytes may be beneficial in the recovery from
experimentally induced PAD. Nevertheless, a knowledge gap remains in
understanding the therapeutic potential of skeletal muscle resident pericytes via
differentiation in postischemic neovascularization following experimentally induced
PAD in T2DM mice. By addressing this knowledge gap, there will be greater
understanding of how diabetes affects the therapeutic potential of pericytes. Future
studies will explore the cellular and molecular mechanisms of pericyte
differentiation and dysfunction in diabetic PAD, as well as therapies to optimize
tissue resident pericyte differentiation potential and enhance neovascularization for
diabetic PAD patients.
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CHAPTER 3
METHODS

Study Design
The first aim of this dissertation was to determine the effect of skeletal
muscle pericyte cell therapy on postischemic neovascularization induced by
hindlimb ischemia in vivo in wild type and T2DM mice. The hypothesis was that
pericyte cell therapy improves neovascularization in wild type recipients compared
to control mice, but that T2DM impairs the efficacy of pericyte cell therapy to
enhance postischemic neovascularization. The second aim of this dissertation was
to determine the in vivo rate of pericyte differentiation into endothelial cells and
skeletal myocytes during neovascularization after induction of hindlimb ischemia in
wild type and T2DM mice. The hypothesis was that the diabetic environment
impairs pericyte differentiation into endothelial cells and skeletal myocytes
compared to the wild type recipient environment (Figure 3.1). Briefly, pericytes
were sorted from murine skeletal muscle and characterized via in vitro
differentiation, surface marker expression, and gene expression. Femoral artery
ligation surgery was used to induce unilateral limb ischemia in wild type or T2DM
mice. Freshly sorted green fluorescent protein-positive (GFP+) pericytes or vehicle
control were intramuscularly transplanted into ischemic hindlimbs, and limb blood
flow recovery was assessed using laser Doppler perfusion imaging (LDPI) at presurgery, post-surgery, and at postoperative days (POD) 3, 7, 14, 21, and 28. At
POD28, the mice were sacrificed, and gastrocnemius and thigh muscles were

34

dissected and cryopreserved. Angiogenesis, including capillary-to-fiber ratio and
capillary density, was assessed in gastrocnemius muscles. Collateral artery
enlargement was assessed in thigh muscles. GFP+ transplanted pericytes were
identified in skeletal muscle sections using immunofluorescence. Confocal
microscopy was used to assess in vivo differentiation via GFP co-staining with
phenotypic markers for satellite cells and endothelial cells or to identify GFP+
muscle cells.
B. Type 2 Diabetes

A. Wild Type

CD146+
pericytes

CD146+
pericytes

Collateral Artery
Enlargement

Collateral Artery
Enlargement

Angiogenesis

Angiogenesis

Figure 3.1 Conceptual Model
Wild type (A) or type 2 diabetic (T2DM; B) mice were transplanted with GFP CD146+
pericytes after the induction of limb ischemia. Postischemic neovascularization, including
foot blood flow, angiogenesis, and collateral artery enlargement were assessed. In vivo
differentiation into endothelial cells and skeletal myocytes was also assessed. It was
hypothesized the pericyte transplantation would augment neovascularization in wild type
mice, but that T2DM would impair the ability of skeletal muscle pericytes to augment
postischemic neovascularization. The second hypothesis was that diabetes would impair
in vivo differentiation of pericytes into endothelial cells and skeletal myocytes.
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Skeletal muscle dissection and dissociation for pericyte isolation
Thigh, gastrocnemius, and tibialis anterior muscles were dissected from the
hindlimbs of male and female 8-12-week-old transgenic mice that ubiquitously
express enhanced Green Fluorescent Protein (GFP) under the direction of the
human ubiquitin C promotor (C57BL/6-Tg(UBC-GFP)30Scha/J; Jackson
Laboratories, Bar Harbor, ME). Skeletal muscle tissue was digested using a protocol
adapted from previous publications146, 147. Briefly, muscle complexes were
dissected, minced with scissors, and digested with type-I, type-II, and type-IV
collagenases (100 mg/ml) in DMEM supplemented with 10% FBS and
penicillin/streptomycin for 1.5 h at 37°C to release cells. Inhibition medium
containing DMEM, 10% FBS, and 1% (v/v) penicillin/streptomycin was added to the
tissue slurries, which was then serially filtered through 100 μm, 70 μm and 40 μm
nylon meshes. The cell suspension was centrifuged, and the cell pellet was
resuspended in cold 2% FBS in Dulbecco’s phosphate buffered saline (DPBS) for
antibody staining and subsequent cell sorting.

Fluorescence activated cell sorting of pericytes
Cells were incubated with anti-mouse CD16/CD32 (1 μg/million cells) for 15
minutes on ice to block non-specific Fc-mediated interactions (BD Biosciences, San
Jose, CA). Next, cells were stained anti-CD45-PE, anti-CD34-BV421, and anti-CD146Alexa647 (BD Biosciences) at 1:100 in 2% FBS in DPBS at 4°C for 20 minutes.
Pericytes were isolated using fluorescence activated cell sorting (FACS) with a BD
FACSAria Cell Sorter (BD Biosciences). The sorting protocol was based on
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previously published methods that showed CD45-CD34-CD56-CD146+ cells were
enriched for pericytes in human skeletal muscle146, 148, 149. Briefly, single cells were
selected based on physical parameters, such as forward and side scatter area,
height, and width; doublet discrimination was also performed. Gating for CD45CD34- cells was used to exclude hematopoietic stem cells and myogenic progenitors.
From the CD45-CD34- fraction, CD146+ cells were selected (Figure 3.2). Gates were
established using fluorescence minus one controls. Compensation was performed
using single stained compensation beads. The isolation and sorting protocol yielded
approximately 1-2% CD45-CD34-CD146+ cells from whole skeletal muscle, and
sorting efficiency ranged from 70-90%. The CD45-CD34-CD146+ fraction was
analyzed to confirm pericyte identity (described below).

Figure 3.2 Fluorescence activated cell sorting schematic for the isolation of pericytes
from skeletal muscle.
Single cell suspensions were attained following skeletal muscle digestion, and cells were
selected based on physical parameters (forward scatter area (FSC-A) and side scatter area
(SSC-A)). Cells were further gated on FSC-A and forward scatter height for doublet
discrimination (data not shown). CD45-CD34- cell population was selected to eliminate
hematopoietic cells and satellite cells. CD146+ cells were selected from the CD45-CD34fraction. These cells were cultured after fluorescence activated cell sorting (FACS) for
use in in vitro differentiation assays. In separate experiments, CD45-CD34-CD146+ cells
were further characterized via flow cytometry for surface marker expression.
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Culturing of freshly sorted primary pericytes
Freshly sorted pericytes were seeded on 0.2% gelatin in MEM alpha (Gibco™
Thermo Fisher Scientific, Waltham, MA) supplemented with 12.5% FBS, 10-4M 2mercaptoethanol, 10-5M hydrocortisone (Stem Cell Technologies, Cambridge, MA),
and 1% penicillin-streptomycin. At 80-90% confluence, pericytes were split 1:1 on
polystyrene tissue culture plates. Cells were then split 1:2 or 1:3 and maintained
until passage 4-5. Cultured cells were used for in vitro differentiation assays.

Pericyte characterization
Pericyte characterization was a critical component of this dissertation due to
the somewhat ambiguous nature of this stem cell population and the lack of a
unique cell surface marker to identify pericytes. It was essential to ensure that these
tissue resident stem cells contained a combination of pericytes markers and were
negative for hematopoietic, myogenic, and endothelial markers. Therefore, flow
cytometry, RT-qPCR, and differentiation assays were used to characterize the CD45CD34-CD146+ pericytes.

In vitro differentiation
Passage 2 cells were seeded in 8-well chamber slides. After 24 hours, the
medium was changed to a selective differentiation medium, as follows: for
adipocytes, MesenCult Basal Medium (STEMCELL Technologies, Vancouver, Canada)
with Adipogenic Stimulatory Supplements (mouse; STEMCELL Technologies) for 21
days; for endothelial cells, Mesencult Basal Medium with 50 ng/ml VEGF
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(STEMCELL Technologies) for 7 days; for osteocytes, StemXVivo Base Medium with
Osteogenic Supplements (R&D Systems, Minneapolis, MN) for 28 days; for muscle,
muscle proliferation medium containing DMEM high-glucose supplemented with
10% FBS, 10% horse serum (HS; Invitrogen™, Thermo Fisher Scientific), 1% chick
embryo extract (CEE; Accurate Chemical, Westbury, NY) for 7 days followed by
lowering the serum concentration from 20% to 2% by replenishing half the medium
every three days over 7-10 days with myogenic (muscle fusion) medium containing
DMEM high-glucose supplemented with 1% FBS, 1% horse serum, and 0.5% chick
embryo extract. Cells were washed and fixed for 20 min at room temperature with
4% paraformaldehyde (PFA), and then immunocytochemistry was performed to
visualize differentiation.
For endothelial cell transdifferentiation, cells were blocked (10% goat serum,
1% BSA; 30 minutes) and then stained with anti-CD31 antibody (1:20 in blocking
solution; Abcam, Cambridge, MA) for 90 minutes at 37°C. Next, cells were washed
and then stained with goat anti-rabbit secondary antibody (1:100 in 1% BSA) for 45
min at 37°C in the dark. Finally, cells were washed, stained with DAPI, washed again,
and mounted. For adipogenesis, cells were washed with 60% isopropanol for 5 min
at room temperature, and then dried completely. Next, Oil Red O working solution
was added to the cells, and cells were incubated for 10 min at room temperature. Oil
Red O was removed and distilled water was immediately added. Images were
acquired after thorough washing. For osteogenesis, cells were permeabilized and
blocked with 0.3% Triton X-100, 1% BSA, and 10% normal donkey serum in PBS at
room temperature for 45 min. Next, cells were stained with the primary anti-
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osteopontin antibody (R&D Systems) at 10 µg/ml in 1% BSA and 10% donkey
serum in PBS at 4°C overnight. Cells were washed then incubated with Alexa-488
conjugated donkey anti-goat secondary antibody at 1:200 for 1 h in the dark at room
temperature. Cells were washed, stained with DAPI, mounted, and then imaged. For
muscle differentiation, cells were permeabilized with 0.2% Tween-20 for 10 min at
room temperature. Cells were then washed and blocked with 10% goat serum and
1% BSA in PBS for 30 min at room temperature. Next, cells were incubated with
anti-MHC primary antibody at 5 µg/ml in PBS for 90 minutes at 37°C. After washing,
cells were stained with goat anti-mouse Dylight549 secondary antibody at 1:100 in
PBS for 1 h in the dark at room temperature. Finally, cells were washed, stained
with DAPI, and then slides were mounted for imaging.

Surface marker characterization
Hindlimb skeletal muscles from GFP+ mice were dissected and dissociated as
described above. Cells were stained 1:100 for 20 minutes at 4°C in 2% FBS with
anti-CD45-BUV395, anti-CD34-BV421, anti-CD146-Alexa647, and a PE-conjugated
antibody against either a mesenchymal cell marker (CD73, CD90, or CD105; BD
Biosciences), the pericyte marker PDGFRβ (Abcam), an endothelial cell marker
(CD144; BD Biosciences), or the appropriate PE-conjugated IgG control. Following
staining, cells were fixed with PFA and resuspended in PBS. Flow cytometry was
performed on a BD Dual LSRFortessa (BD Biosciences). Gates were established
using fluorescence minus one controls; single stained controls were used for
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compensation. The percentage of PE+ CD45-CD34-CD146+ cells was determined for
each surface marker.

RT-qPCR
The RNAqueous-Micro Kit (Ambion, Thermo Fisher Scientific) was used to
isolate total RNA from 2x105 freshly sorted CD45-CD34-CD146+ pericytes per
manufacturer’s instructions. Briefly, pericytes were washed in PBS, and then
resuspended in 100 µl of lysis buffer via repeat pipetting with a 1 ml sterile syringe.
At this point, cells were frozen in lysis buffer at -80°C until RNA isolation and cDNA
synthesis could be completed. To complete RNA isolation, the lysate was washed
with ethanol and passed through a column to bind RNA. Next, the filter was washed,
and the flow through was discarded. RNA was eluted into a clean elution tube. RNA
concentration was determined via NanoDrop Spectrophotometry. cDNA synthesis
was performed using Superscript III First-Strand Synthesis SuperMix (Invitrogen,
Thermo Fisher Scientific Corporation, Carlsbad, CA) per manufacturer’s
instructions. Briefly, 20 µl reactions were prepared with 100 ng of RNA for control
and experimental samples. A thermocycler was programmed to incubate the
samples at 25°C for 10 minutes, 50°C for 30 min, then 85°C for 5 min. Samples were
moved to ice, then 1 μl of E. coli RNase H was added and the sample was incubated
at 37°C for 20 minutes. cDNA was stored at -20°C prior to qRT-PCR. Control RNA
was isolated and cDNA was synthesized from muscle tissue homogenates side-byside with experimental pericyte RNA isolation and cDNA synthesis. qRT-PCR was
performed with Kapa SYBR FAST qPCR kit (Kapa Biosystems, Boston, MA) per
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manufacturer’s instructions. Briefly, 1.5 μl of cDNA template was used in 20 μl
reactions. Reactions were run in triplicate. The average cycle threshold (Ct) for each
triplicate was used for data analysis. Differences in relative gene expression were
determined using the ΔΔCt method. BestKeeper Excel-based tool, which utilizes
pairwise correlations to determine a stably expressed housekeeping gene150, was
used to create an index of most suitable reference genes from five potential genes
(eukaryotic elongation factor 2 (Eef2), aryl-hydrocarbon receptor-interacting
protein (Aip), ribosomal protein L38 (Rpl38), CXXC-type zinc finger protein 1
(Cxxc1), and beta-actin (Bact)); As a result of the BestKeeper analysis, the Ct values
for Cxxc1 and Eef2 were averaged and used as the reference Ct value. Primer
sequences are presented in Table 3.1.
Gene

Forward Primer (5'-3')

Reverse Primer (3'-5')

Pax3
Pax7
Cd31
Sca1
Myod

AGTGCAGGTCTGGTTTAGCA
CTCCTCAGGTCATGAGCATCC
GTCATGGCCATGGTCGAGTA
TTCTCTGAGGATGGACACTTCT
GCTACCCAAGGTGGAGATCCT

GGTCTCCGACAGCTGGTAT
GTGGGCAGTAAGACTGGGAC
TCCTCGGCGATCTTGCTGAA
GGTCTGCAGGAGGACTGAGC
GGCGGTGTCGTAGCCATT

Eef2
Rpl38
Aip
Bact
Cxxc1

CTGGTGGAGATCCAGTGTCC
GTTCTCATCGCTGTGAGTGT
GCTCCGTTATAGATGACAGC
CCTCTATGCCAACACAGTGC
CAGACGTCTTTTGGGTCCA

GCCTTGACCACAAACATGGG
TTGACAGACTTGGCATCCTTCC
ATCTCGATGTGGAAGATGAG
CATCGTACTCCTGCTTGCTG
AGACCTCATCAGCTGGCAC

Table 3.1 qRT-PCR primers.
Pax3 paired box 3; Pax7 paired box 7; Cd31 cluster of differentiation 31; Sca1 stem cell
antigen 1; Myod myogenic differentiation; Eef2 eukaryotic elongation factor 2, Rpl38
ribosomal protein L38; Aip aryl-hydrocarbon receptor-interacting protein, Cxxc1 CXXCtype zinc finger protein 1, and Bact beta-actin.
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Animals
Three-month-old, male wild type (C57BL/6, Jackson Laboratories; n=12) and
leptin receptor deficient db/db T2DM mice (B6.Cg-m +/+ Leprdb/J mice, Jackson
Laboratories; n=10) underwent induction of limb ischemia, and were the recipient
mice for pericyte cell transplant or vehicle control transplant. Mice that ubiquitously
express enhanced Green Fluorescent Protein (GFP) under the direction of the
human ubiquitin C promotor (C57BL/6-Tg(UBC-GFP)30Scha/J; Jackson
Laboratories, Bar Harbor, ME) were the donor mice for pericyte isolation and
transplantations. All mice were fed ad libitum using a standard chow that contains
5.7% fat by weight. The Institutional Care and Use Committee of the University of
Massachusetts Medical School approved all animal protocols.

Hindlimb ischemia
Unilateral femoral artery ligation surgery was used to induce hindlimb
ischemia via a rapid reduction of blood flow to the left hindlimb. This model
stimulates postischemic neovascularization in the ischemic hindlimb134, 136, 144, 151.
One day prior to surgery, mice were placed under anesthesia with 1-2% isoflurane
for hair removal of the hindlimbs via shaving and Nair hair removal cream. During
surgery, mice were placed under anesthesia with 1-2% isoflurane. A small incision
was performed near the inguinal ligament of the left hindlimb. The femoral
neurovascular bundle was located, and the femoral artery was isolated from the
nerve and vein. Next, the artery and its branches were ligated from the inguinal
ligament to the popliteal bifurcation. The artery was excised. Then, the incision was
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sutured. The contralateral limb was not operated on and served as a control.
Animals recovered in cages. For pain relief, the analgesic buprenorphine was
administered subcutaneously pre-surgery, 4h post-surgery, and as needed for 48h
at 0.1 mg/kg; the analgesic ketoprofen was administered subcutaneously presurgery and 24h post-surgery at 5 mg/kg.

Pericyte transplantation
Pericytes from GFP+ mice were sorted as previously described. One-day postinduction of limb ischemia, wild type (n=6) and T2DM mice (n=5) were injected
with 1x105 freshly isolated pericytes that were suspended in 150 μl of sterile PBS.
Control wild type (n=6) and control T2DM mice (n=5) were injected with vehicle
control (sterile PBS only). Injections were done under 1-2% isoflurane anesthesia
intramuscularly into ischemic hindlimbs at three sites in the thigh region and two
sites in the gastrocnemius (30 μl/site).

Hindlimb blood flow recovery
Blood flow in both hindlimb feet was simultaneously assessed noninvasively
pre-surgery, immediately post-surgery, and then on postoperative days (POD) 3, 7,
14, 21 and 28 via Laser Doppler Perfusion Imaging (LDPI; Moor Instruments Ltd.,
Devon, UK). Hindlimb fur was removed on the day prior to LDPI assessment. For
blood flow assessment, mice were placed under anesthesia with 1.5% isoflurane on
a heated 37°C surface. LDPI was used to simultaneously measure blood flow to both
hindlimb feet. Three repeated trials of flow data were collected and averaged. Data
were expressed as a ratio of ischemic vs. non-ischemic hind foot.
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Angiogenesis
Gastrocnemius muscles, which are in the ischemic region, were dissected at
28 days post-induction of hindlimb ischemia and then frozen at -80°C in OCT.
Gastrocnemius muscles were sectioned to 10 µm for immunofluorescent analysis.
Capillaries were stained using a primary antibody against CD144 (1:40, 4°C
overnight; BD Biosciences) followed by secondary antibody staining with Alexa594
conjugated goat anti-rat IgG (1:100 for 2 h at room temperature). Sections were
DAPI mounted (ProLong® Diamond Antifade Mountant with DAPI; Thermo Fisher
Scientific Corporation) and imaged at 20x. Five random images per muscle section
were taken. Two blinded observers counted CD144+ capillaries and muscle fibers;
counts from both observers were averaged for data analysis. Capillary-to-fiber ratio
was expressed as the ratio of CD144+ cells to myofibers. Capillary density was
quantified via the number of CD144+ capillaries per muscle fiber area. Muscle fiber
area was assessed in Adobe Photoshop (Adobe Photoshop CC 2015) using the
magnetic lasso tool to trace muscle fibers.

Collateral Artery Enlargement
Thigh muscles, which are in the region of collateral artery enlargement, were
dissected at 28 days post-induction of hindlimb ischemia and then frozen at -80°C in
OCT. Thigh muscles were sectioned to 10 µm for immunofluorescent analysis. For
the detection of collateral arteries, thigh cryosections were stained with anti-CD144
antibody (1:40, 4°C overnight; BD Biosciences) followed by secondary antibody
staining with Alexa594 conjugated goat anti-rat IgG (1:100 for 2 h at room
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temperature); and then sequentially stained with anti-αSMA (1:2 at 4°C overnight;
Invitrogen, Thermo Fisher Scientific Corporation) followed by secondary antibody
staining with Dylight 488 conjugated goat anti-mouse subclass 2a (1:100 for 2 h at
room temperature). Sections were DAPI mounted (ProLong® Diamond Antifade
Mountant with DAPI; Thermo Fisher Scientific Corporation) and all collateral
arteries were imaged at 20x. Images were analyzed by a blinded observer using
Adobe Photoshop (Adobe Photoshop CC 2015). Collateral vessels were identified
though positive αSMA staining and a visible lumen. Since compression artifacts can
confound diameter measurements, the perimeter of the inner vessel wall was
measured using the magnetic lasso tool, and then perimeter was converted to vessel
diameter, as previously described152.

In vivo pericyte differentiation
Due to high amounts of skeletal muscle autofluorescence, direct GFP
visualization was not possible. Therefore, to determine if GFP+ transplanted
pericytes differentiated during neovascularization, immunofluorescence was used
to investigate costaining of GFP and phenotypic markers of terminal cell types. First,
gastrocnemius and thigh muscles from mice that were transplanted with pericytes
were cryosectioned at 8 μm onto slides preheated to 45°C. To prevent GFP
solubilization, sections were immediately fixed in fresh 37% paraformaldehyde at
45°C. Antigen retrieval was performed with Retrieve-All Antigen Unmasking System
2 (Basic pH 10; BioLegend, San Diego, CA) by microwaving for 10 min, followed by
cooling to room temperature for 30 minutes. Non-specific binding was prevented by
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blocking with 5% donkey serum, 0.2% BSA, and 0.3% Triton-X100 in PBS for 2 h at
room temperature. Sections were incubated with anti-GFP antibody (Ab6673,
Abcam, Cambridge, MA) at 10 µg/ml in blocking solution overnight at 4°C followed
by incubation with Alexa Fluor 568 donkey anti-goat IgG secondary antibody at 10
µg/ml in PBS for 2 h at room temperature. To confirm antibody specificity, the
following controls were used: a wild type tissue negative control, an IgG negative
control, and a GFP positive control. Following anti-GFP labeling, tissue sections were
blocked with 5% goat serum, 0.2% BSA, and 0.3% Triton-X100 in PBS for 2 h. Then,
to visualize either endothelial cells, collateral arteries, or Schwann cells,
respectively, sections were sequentially incubated with one of the following
antibody combinations: anti-CD144 (1:40, 4°C overnight; BD Biosciences) followed
by secondary antibody staining with Alexa594 conjugated goat anti-rat IgG (1:100
for 2 h at room temperature), anti-⍺SMA (1:2, 4°C overnight; Invitrogen) followed
by secondary antibody incubation with Dylight 488 conjugated goat anti-mouse
secondary antibody (1:100 for 2 h at room temperature), or FITC-conjugated antis100 antibody (1:50, 2 h at room temperature; Ab76749, Abcam). Sections were
washed in PBS, dried, and then DAPI mounted. To determine if transplanted
pericytes differentiated, a Nikon A1 Spectral Detector Confocal microscope was used
to scan the tissues at 20x for instances of co-staining. High magnification (60x)
images were acquired to confirm co-staining. Images were also taken of all collateral
arteries, and the percentage of GFP+ collateral arteries was quantified. For skeletal
muscle differentiation, tissues were examined for GFP+ muscle fibers based on GFP
immunofluorescence and morphological characteristics of myofibers.
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Statistical analysis
Results are expressed as mean±standard error of the mean (SEM). Linear
mixed models (fixed effects: time and transplant group; random effect: mouse) were
used to determine differences in blood flow recovery over time between
experimental and control transplantation groups. Tukey’s post-hoc testing was used
to determine differences between control and experimental groups at each time
point. Student’s t tests were used to test for differences in capillary-to-fiber ratio,
capillary density, and collateral diameter between experimental and control groups.
Student’s t tests were used to test for differences in GFP+ pericyte engraftment
between wild type and T2DM groups. Significance was accepted at an α-level of
p≤0.05.
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CHAPTER 4
RESULTS

CD45-CD34-CD146+ skeletal muscle cells are predominately pericytes
Freshly sorted CD45-CD34-CD146+ skeletal muscle cells are predominately
pericytes based on characterization of cell surface markers and gene expression.
Cell surface marker characterization showed that the sorted CD45-CD34-CD146+
cells were predominately positive for two out of three traditional mesenchymal
stem cell (MSC) markers, CD105 (65%) and CD90 (74%), while the sorted CD45CD34-CD146+ cells were mostly negative for the MSC marker CD73 (7.9%). Cells
were weakly positive for the endothelial cell marker, CD144 (36%), and positive for
the pericyte marker PDGFRβ (42%). Taken together, these data show that a
majority of the sorted cells express pericyte surface markers and are mostly
negative for endothelial cells (Figure 4.1, panel A).
Gene expression data further confirmed the pericyte phenotype (Figure 4.1,
panel B). There was significantly greater stem cell antigen-1 (Sca-1) gene expression
in the sorted CD45-CD34-CD146+ skeletal muscle cells than in the whole muscle
tissue homogenate (4.0-fold; p<0.01). There was significantly lower CD31 gene
expression in the sorted CD45-CD34-CD146+ skeletal muscle cells than in the whole
muscle tissue homogenate (0.2-fold, p<0.01). There was no difference in Pax3, Pax7,
or MyoD gene expression in the sorted CD45-CD34-CD146+ skeletal muscle cells
than in the whole muscle tissue homogenate (Pax3: 1.3-fold, Pax7: 1.0-fold, and
MyoD: 1.0-fold, respectively; p>0.05).
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Pericytes are also characterized by their ability to differentiate into
mesodermal lineages. Sorted CD45-CD34-CD146+ skeletal muscle cells differentiated
in vitro into muscle cells, adipocytes, osteocytes, and transdifferentiate into
endothelial cells (Figure 4.1, panel C). In myogenic differentiation medium, pericytes
differentiated into elongated, multinucleated cells that were positive for myosin
heavy chain (MHC). In adipogenic medium, pericytes differentiated into adipocytes
that stained positive for Oil Red O. In osteogenic differentiation medium, pericytes
differentiated into cells that stained positive for osteopontin. After seven days in
endothelial cell transdifferentiation medium, cells expressed the endothelial cell
marker CD31.
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Figure 4.1 Surface marker expression, gene expression, and in vitro differentiation
of CD45-CD34-CD146+ skeletal muscle cells.
A: Cell surface marker expression for mesenchymal stem cell (CD73, CD90, and
CD105), endothelial (CD144), and pericyte (PDGFRβ) markers. B: Gene expression
in pericytes relative to gene expression in muscle tissue homogenate (dashed line)
for stem cell antigen-1 (Sca1), paired box 3 (Pax3), paired box 7 (Pax7), CD31, and
myogenic differentiation 1 (MyoD). C: In vitro differentiation of CD45-CD34-CD146+
cells into skeletal muscle (ii), adipocytes (iii), osteocytes (iv), endothelial cells (v)
and undifferentiated cells (i). Scale bar is 100 µm. *indicates p<0.05 vs. control.

Pericyte transplantation augments blood flow recovery in wild type, but not
T2DM mice
Pericytes or vehicle control were transplanted into the ischemic hindlimbs of
wild type and T2DM mice, and blood flow recovery was assessed via LDPI. Blood
flow was assessed pre-surgery, post-surgery, and at post-operative days (POD) 3, 7,
14, 21, and 28.
In wild type control mice where ischemia was induced and then vehicle
control was transplanted (Control à WT group, n=6), blood flow recovery in the
ischemic foot relative to blood flow in the contralateral control foot reached
61.9±5% by POD28. In the wild type mice that were transplanted with pericytes
following the induction of limb ischemia (Pericyte à WT group, n=6), blood flow
recovery in the ischemic foot reached 79.3±5% relative to blood flow in the
contralateral control foot. Overall in the wild type mice, there was a significant main
effect of transplant (p=0.03) and a trend towards a Time x Transplant interaction
(p=0.09), whereby the mice that received a pericyte transplantation had greater
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blood flow recovery than the control mice at POD28 (24.6% increase; p=0.04)

Figure 3. CD146+ skeletal muscle pericytes augment postischemic
revascularization
(Figure 4.2).in wildtype but no diabetic mice
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Figure 4.2 Blood flow recovery from hindlimb ischemia in wild type mice.
A: Foot blood recovery assessed by LDPI (mean±SEM, n=6 per group, *p<0.05 vs
ControlàWT). B: Representative LDPI images at each time point. WT indicates wild
type; POD indicates post-operative day; LDPI indicates laser Doppler perfusion
imaging; “à” indicates “transplanted into”.

Overall, T2DM mice had significantly lower blood flow than wild type mice
during the recovery from limb ischemia (p<0.001). Within T2DM mice, the control
mice where ischemia was induced and then vehicle control was transplanted
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(Control à T2DM group, n=5), blood flow recovery in the ischemic foot reached
46.3±5% relative to blood flow in the contralateral control foot. In T2DM mice that
were transplanted with pericytes following the induction of limb ischemia (Pericyte
à T2DM group, n=5), blood flow recovery in the ischemic foot reached 48.6±6%
relative to blood flow in the contralateral control foot. Overall in the T2DM groups,
there was no main effect of transplant (p=0.51), and no Time x Transplant
interaction (p=0.96); therefore, pericyte transplantation did not augment blood flow

Figure 3. CD146+ skeletal muscle pericytes augment postischemic
revascularization
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no diabetic
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Figure 4.3 Blood flow recovery from hindlimb ischemia in T2DM mice.
A: Foot blood recovery assessed by LDPI (mean±SEM, n=5 per group). B:
Representative LDPI images at each time point. T2DM indicates type 2 diabetes
mellitus db/db mice; POD indicates post-operative day; LDPI indicates laser Doppler
perfusion imaging; “à” indicates “transplanted into”.

Pericyte transplantation augments collateral artery enlargement in wild type,
but not T2DM mice
At POD28, ischemic thigh muscles were dissected and cryopreserved for
histological analysis of collateral artery diameter. In wild type mice, the average
collateral artery diameter was 17.9% greater in mice that were transplanted with
pericytes compared to mice transplanted with vehicle control (26.7±2 μm vs. 22.3±1
μm, p=0.03). In T2DM mice, the average collateral artery diameter was not
significantly different between mice transplanted with pericytes or vehicle control
(9.7% difference; 20.4±1.4 μm vs. 18.5±1.2 μm, p=0.14) (Figure 4.4).

54

Figure 4. CD146+ pericyte transplantation enhances collateral artery enlargement, but not angiogenesis
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Figure 4.4 Collateral artery diameter in wild type and T2DM mice induced by
postischemic neovascularization.
Collateral artery diameter was assessed in the thigh muscles of (A) WT mice
(means±SEM, n=6, *p=0.03 vs. ControlàWT) and (B) T2DM (means±SEM, n=5) at
POD28 following the induction of limb ischemia. Representative images (C) of
* Significantly greater than Control à WT (p=0.03)
are means±SEM
CD144 (red) and ⍺-SMA (green)Data
double
staining of collateral vessels (DAPI in blue).
Scale bars are 50 µm. WT indicates wild type, T2DM indicates type 2 diabetes
mellitus db/db mice.
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Pericyte transplantation does not improve angiogenesis
At POD 28, gastrocnemius muscles, which are the site of angiogenesis, were
dissected and cryopreserved for quantification of angiogenesis via capillary density
and capillary-to-fiber ratio. In wild type mice, pericyte transplantation nonsignificantly increased capillary density by 12% compared to mice transplanted
with vehicle control (453.2±34 capillary/mm2 vs. 508.3±66; p=0.16). In T2DM mice,
pericyte transplantation did not increase capillary density (3% difference)
compared to mice transplanted with vehicle control (550.7±47 capillary/mm2 vs.
569.8±105; p=0.46). There were no differences in capillary-to-fiber ratio in the
pericyte transplanted mice compared to vehicle control for wild type (1.26±0.06 vs.
1.18±0.04; p=0.23) or T2DM mice (0.99±0.07 vs. 1.00±0.05; p=0.44) (Figure 4.5).
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Figure 4. CD146+ pericyte transplantation enhances collateral artery enlargement, but not angiogenesis
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Figure 4.5 Angiogenesis in wild type and T2DM mice induced by postischemic
neovascularization.
Angiogenesis was assessed in the gastrocnemius muscle via capillary density in (A)
wild type mice (means±SEM, n=6) and (B) T2DM (means±SEM, n=5) at POD28
following the induction of limb ischemia. Angiogenesis was also assessed via
capillary-to-fiber ratio in (C) wild type mice (means±SEM, n=6) and (D) T2DM
(means±SEM, n=5) at POD28. Representative images (E) show CD144
immunofluorescence and phase contrast images taken for quantification from wild
type (top panel) and T2DM (bottom panel) mice. WT indicates wild type, T2DM
indicates type 2 diabetes mellitus db/db mice. Scale bar is 50 µm.
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Transplanted pericytes incorporate into host vasculature and nerves, but not
skeletal muscle in vivo
Skeletal muscles from ischemic hindlimbs that were cryopreserved at POD28
were analyzed for GFP+ pericyte transdifferentiation into endothelial cells by
examining GFP co-staining with CD144. In both wild type and T2DM mice, instances
of CD144 and GFP double staining were observed in presumed collateral vessels
(Figure 4.6, panel A). To confirm that GFP+ pericytes were incorporating into
collateral vessels, skeletal muscles were examined for instances of double positive
GFP+ and ⍺SMA+ collateral vessels. There was a significantly greater percentage of
⍺SMA+ collateral vessels that co-stained positive for GFP in wild type mice
compared to T2DM mice (25.0±1% vs. 11.3±3%, respectively; p=0.002) (Figure 4.6).
GFP+ cells were also observed near collateral vessels. Morphology suggested
that these positive cells were neural in origin, possibly Schwann cells. To investigate
GFP+ pericyte differentiation into Schwann cells, skeletal muscle sections were
examined for double staining of GFP and the Schwann cell marker, S100. In both
wild type and T2DM mice, costaining of GFP and S100 was observed, confirming
that pericytes differentiated into Schwann cells (Figure 4.7).
No evidence of pericyte differentiation into skeletal muscle cells was
observed in gastrocnemius or thigh muscle sections of wild type or T2DM.
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Figure 4.6 In vivo engraftment of GFP+ pericytes into collateral vessels.
GFP+ pericyte differentiation into CD144+ endothelial cells was assessed WT (A, top
panel) and T2DM mice (A, bottom panel) in skeletal muscles at POD28 following the
induction of limb ischemia. GFP+ pericyte engraftment into ⍺SMA+ collateral vessels
was assessed in WT (B, top panel) and T2DM mice (B, bottom panel) in thigh
muscles at POD28 following the induction of limb ischemia. Engraftment was
quantified as the percentage of total ⍺SMA+ collateral vessels that co-stained positive
for GFP (C). WT indicates wild type, T2DM indicates type 2 diabetes mellitus db/db
mice, GFP indicates green fluorescent protein, ⍺SMA indicates alpha smooth muscle
actin, POD28 indicates postoperative day 28. Scale bar is 50 µm.
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Figure 4.7 In vivo differentiation of GFP+ pericytes into Schwann cells.
GFP+ pericyte differentiation was investigated in the skeletal muscles of wild type and
T2DM mice at POD28 by examining GFP co-staining with the Schwann cell marker
S100. GFP indicates green fluorescent protein, WT indicates wild type, T2DM indicates
type 2 diabetes mellitus db/db mice.
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CHAPTER 5
DISCUSSION
Skeletal muscle pericytes augment postischemic neovascularization in wild
type mice, but T2DM impairs the ability of skeletal muscle pericytes to augment
postischemic neovascularization. The main findings of this study are: 1) skeletal
muscle pericytes can be prospectively isolated from murine skeletal muscle; 2) in
wild type mice, skeletal muscle pericyte cell therapy augments blood flow recovery
via collateral artery enlargement, but not angiogenesis; 3) in T2DM mice, pericyte
cell therapy does not augment blood flow recovery, collateral artery enlargement, or
angiogenesis; 4) pericytes engraft into host collateral arteries at a higher percentage
in wild type compared to T2DM mice; and 5) pericytes differentiate into Schwann
cells in vivo. The implications of this study are that pericyte cell therapy may be a
novel treatment strategy to improve blood flow in PAD, but not for T2DM patients
with PAD. Future studies should identify the mechanisms by which the diabetic
environment impairs the efficacy of pericyte cell therapy in order to find ways to
overcome the limitation of this potential stem cell treatment.
Pericytes can be prospectively isolated from murine skeletal muscle. In this
study, fluorescence activated cell sorting was used to isolate CD45-CD34-CD146+
pericytes. Previous work identified CD45-CD34-CD56-CD146+ cells from human
skeletal muscle as pericytes7, 146. In the present study, the same isolation protocol
was followed except for gating out a CD56 cell population, which is not necessary in
murine skeletal muscle147, 153, 154. Since the isolation protocol is established for
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sorting skeletal muscle pericytes from human tissue, the characterization of murine
skeletal muscle pericytes was required.
There is no well-established surface marker profile for murine skeletal
muscle pericytes; therefore, a combination of surface marker expression, in vitro
differentiation, and gene expression was used to identify and characterize CD45CD34-CD146+ skeletal muscle cells as pericytes. In this study, as well as in
previously published work, pericytes express the surface markers PDGFRβ and
CD1467, 129, 140, 147, 155. Skeletal muscle pericytes have also been identified via the
pericyte markers NG2 and alkaline phosphatase (ALP)7, 140, although these markers
were not used in this study. Crisan and colleagues156 demonstrated that cells
expressing pericyte markers also displayed MSC surface markers and in vitro
differentiation characteristics similar to MSCs. In this study, pericytes expressed the
MSC markers CD90 and CD105, but were negative for CD73. It is unknown why the
cells were positive for only two out of three MSC surface markers. Pericyte
phenotype was further characterized in the present study through in vitro
differentiation assays that showed myogenic, adipogenic, and osteogenic
differentiation potential, hallmarks of the pericyte phenotype. The data also showed
endothelial transdifferentiation potential, which may have important implications
for PAD therapeutic potential. In vitro pericyte differentiation into myogenic,
adipogenic, and osteogenic lineages has also been shown in CD45-CD34-CD56CD146+ human skeletal muscle pericytes7. Finally, the data from this study showed
enhanced Sca1 gene expression in CD45-CD34 -CD146+ cells, indicating a stem or
progenitor cell phenotype, while also demonstrating the absence of contamination
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from muscle, satellite, or endothelial cells, as indicated by low gene expression of
MyoD, Pax3, Pax7, and Cd31. Valero and colleagues147 also showed that a
perivascular stem cell population from skeletal muscle, likely pericytes, were CD45Sca1+; and they demonstrated that the pericyte population was not contaminated
with satellite cells or endothelial cells, but may be useful in disease therapy. In
summary, the combination of characterization methods utilized in this study
identified the CD45-CD34-CD146+ skeletal muscle cells as pericytes.
Using the prospectively isolated and characterized pericytes, a major finding
of this project is that pericyte cell therapy improves recovery from limb ischemia via
increased collateral artery enlargement. In this study, wild type mice that were
transplanted with pericytes recovered more blood flow to their ischemic limbs than
wild type mice transplanted with a vehicle control. At 28 days after the induction of
ischemia, the pericyte transplanted group recovered 17.5% more blood flow than
the control transplanted mice. Previous studies have also shown the therapeutic
potential of skeletal muscle pericytes or similar cells to improve postischemic
neovascularization in a murine limb ischemia model10, 129, 139-141. Birbrair and
colleagues140 qualitatively showed that Nestin+NG2+ pericytes improve recovery
from ischemia via incorporation into newly formed vessels 10 days after the
induction of limb ischemia in athymic nude mice, but foot blood flow recovery was
not quantified. In another study, perivascular cells derived from human pluripotent
stem cells (hPSCs) were shown to improve foot blood flow recovery via
incorporation into both muscle and vasculature in immunodeficient mice139.
Gubernator and colleagues141 transplanted saphenous vein adventitial progenitor
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cells, a cell type that expresses NG2 and PDGFRβ, into immunodeficient mice and
showed improved recovery from limb ischemia at postoperative day 28. In that
study, the improvement in blood flow recovery in transplanted mice compared to
control mice was similar to the improvement in blood flow recovery that was
observed in the present study141. Each of these studies show that perivascular cells
can aid in recovery from limb ischemia, but their translatability to human disease is
limited by using an immunodeficient mouse model. Immunodeficient mouse models
decrease the chances of a stem cell therapy to cause an adverse immune reaction or
cell rejection. However, an immunocompetent host, like the model used in this
study, is more translatable to human disease therapy.
In this study, postischemic neovascularization was enhanced via collateral
artery enlargement in the wild type mice receiving pericyte transplantation.
Collateral artery enlargement is the main mechanism for increasing blood flow to
the ischemic limbs in the murine model of limb ischemia138. To date, only one
previous study has used the murine limb ischemia model to examine the role of
pericytes to augment postischemic neovascularization and collateral artery
enlargement. Birbrair and colleagues140 used in vivo MRI angiography to
qualitatively show collateral remodeling in the ischemic hindlimbs of mice following
pericyte cell transplantation. Additionally, bone marrow MSC transplantation was
shown to increase collateral artery enlargement following the induction of limb
ischemia in mice10.
Blood flow recovery can also be augmented via angiogenesis; however,
pericyte cell therapy did not improve angiogenesis in this study, as assessed by
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capillary-to-fiber ratio and capillary density. In contrast to the findings of this study,
Dar et al.139 observed increased blood vessel density in ischemic limbs transplanted
with pericytes compared to non-transplanted controls. While there are few studies
that examine the effect of pericyte transplantation on angiogenesis during
postischemic neovascularization, MSCs have been shown to improve angiogenesis
during postischemic neovascularization in wild type mice10. It is unknown why
pericyte transplantation did not significantly improve angiogenesis in this study, but
may represent an important difference between mechanisms of blood flow recovery
between skeletal muscle pericytes and similar cell types, like MSCs.
Stem cell therapies are known to be less effective due to diabetes10, 142.
Therefore, preclinical models should test the efficacy of stem cell therapies in
diseased animals in addition to wild type animals. Yan et al.10 tested the efficacy of a
mesenchymal stem cell therapy to augment postischemic neovascularization in
immunocompetent wild type and T2DM mice. They found that although MSCs could
augment postischemic neovascularization in wild type mice by 15% (79±2% vs.
64±1% in controls), diabetes impaired the ability of MSCs to augment postischemic
neovascularization. This study highlights the negative impact that concomitant
disease can have on stem cell therapy. In the present study, the efficacy of a pericyte
cell therapy was tested in the same clinically relevant T2DM of PAD. It was found
that the T2DM environment impairs the ability of pericytes to augment
postischemic neovascularization.
Skeletal muscle pericyte transplantation into immunocompetent T2DM mice
does not improve blood flow recovery, collateral artery enlargement, or
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angiogenesis following the induction of limb ischemia. While the mechanisms by
which the diabetic environment impairs the ability of skeletal muscle pericytes to
augment postischemic neovascularization were not examined, previous studies
indicate that T2DM alters oxidant stress which may negatively impact stem cell
therapy10. Furthermore, an investigation of human skeletal muscle pericytes from
diabetic patients with critical limb ischemia showed that diabetic pericytes had
increased oxidant stress compared to pericytes from donors without diabetes129.
Type 1 diabetes, although different from T2DM, is also an inflammatory and
autoimmune disease. Caporali and colleagues145 used a type 1 diabetes model to
demonstrate impaired recovery from limb ischemia in mice. They provided
evidence to suggest that diabetes impairs endothelial cell inflammatory signaling
and pericyte-endothelial cell crosstalk. Together with the current study, evidence
suggests that disease, especially T2DM, can negatively impact pericytes for use in a
stem cell therapy.
Another major finding of this study is that pericytes differentiate in vivo
during postischemic neovascularization, even in T2DM mice. As previously
discussed, pericytes differentiate into muscle and transdifferentiated into
endothelial cells in vitro. Similar to reports from previous publications139, 140,
transplanted pericytes are found near existing vasculature. It was hypothesized that
pericytes augment angiogenesis and differentiate into capillary endothelial cells;
however, pericytes do not improve angiogenesis and they appear to differentiate
into the endothelial cell layer of collateral arteries in the thigh muscles.
Incorporation into collateral vessels was confirmed in both wild type and T2DM
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mice, but T2DM impaired the incorporation of skeletal muscle pericytes into
collateral vessels in vivo. Incorporation into collateral vessels may be the
mechanism by which pericytes improve collateral artery enlargement in wild type
but not T2DM mice following the induction of limb ischemia. In support of this
study, previous studies have also shown that T2DM negatively affects stem cell
differentiation10, 129. Yan et al.10 showed that T2DM impaired the in vivo
differentiation capacity of transplanted MSCs in mice10 by skewing differentiation
away from endothelial cells and towards adipocytes following the induction of limb
ischemia. Similarly in humans, pericytes isolated from the skeletal muscles of
diabetic patients had skewed in vitro differentiation towards adipocytes129.
Adipogenic differentiation of pericytes was not investigated in the current study,
nor was it informally observed. A likely mechanism for the altered differentiation
capacity in T2DM mice may be diabetes-induced oxidant stress10, 129. Future studies
should examine if reducing oxidant stress can improve the ability of skeletal muscle
pericytes to augment postischemic neovascularization and incorporation into
collateral vessels in T2DM mice.
Collateral vessels that were positive for pericyte incorporation were often
observed near GFP+ structures that were identified as Schwann cells, indicating that
pericytes differentiated into Schwann cells. Schwann cells are glial cells of the
peripheral nervous system that support axons and are involved in nerve repair and
myelination157. Previous studies have shown that perivascular cells from the central
nervous system can be induced to express glial markers in vitro158. Further, a
population of nestin+ skeletal muscle neural precursors were identified by Birbrair
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and colleagues159 and shown to possess gliogenic potential, thus demonstrating the
possibility of skeletal muscle resident cells to contribute to peripheral nervous
system glial cells in vivo. Differentiation of skeletal muscle pericytes towards glial
cells during postischemic neovascularization may be an important component of
overall tissue recovery. Interestingly, differentiation into Schwann cells was
observed in both wild type and T2DM mice. Peripheral neuropathy is a negative
consequence of T2DM, and a cell therapy that is designed to increase blood flow
while also treating neuropathy would be beneficial to diabetic patients with PAD
and warrants further investigation into the mechanism of pericyte gliogenic
differentiation in vivo.
Contrary to the hypothesis, there was no indication of pericyte
differentiation into skeletal myocytes in vivo in wild type or T2DM mice. Previous
studies have shown that perivascular cells can incorporate into skeletal muscle139,
but that was not observed in this study. Reasons for the lack of myogenic
differentiation could include differences in the number or type of transplanted cells.
For example, Dar et al.139 transplanted 2x106 human-induced pluripotent stem cells
into immunodeficient mice following the induction of limb ischemia and observed
myogenic differentiation, whereas 1x105 skeletal muscle pericytes were
transplanted into immunocompetent hosts in this study. There could be several
reasons why skeletal myogenic differentiation was not detected after
transplantation of 1x105 pericytes. First, myogenic differentiation may not have
occurred in this model. Second, myogenic differentiation may have occurred
infrequently, but was not observed in the skeletal muscle sections that were

68

examined. Or finally, perhaps pericytes fused with existing multinucleated muscle
fibers, but the GFP signal was too weak to detect.
The present study is strengthened by its relevance to human disease therapy.
This study utilized a clinically relevant model of PAD in immunocompetent mice to
study postischemic neovascularization and in vivo differentiation of skeletal muscle
pericytes, a novel stem cell candidate for PAD therapy. This study demonstrated a
clinically meaningful increase in hindlimb blood flow in wild type mice that received
pericyte transplantation. While there is no way to directly correlate the degree of
neovascularization seen in this preclinical mouse study to neovascularization in
human clinical trials, a 17.5% improvement in blood flow would likely be a clinically
significant improvement in disease state in a human population. This study also
highlights the utility of isolating pericytes from skeletal muscle for immediate use in
disease therapy. The isolation protocol yielded between 1-2x105 pericytes from the
hindlimb skeletal muscles of one mouse, which generated enough cells for
immediate transplantation. In comparison, both HSCs and MSCs, two candidate cell
types for a variety of disease therapies, are typically expanded in vitro prior to use in
cell therapy. By eliminating in vitro expansion, there is less risk of cell
contamination or phenotypic alterations due to in vitro culturing; and furthermore,
future stem cell therapies can be delivered to patients more quickly.
The current study also has some limitations. First, the clinical relevance is
limited by using an acute PAD model in young mice. PAD is a progressive disease
that is often seen in the aging population; therefore, using an aged mouse model and
a progressive ischemia model would increase the clinical relevance. Second, the
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study is limited because it examines the negative impact of the diabetic environment
on the ability of pericytes to augment postischemic neovascularization, but it does
not examine the ability of pericytes from diabetic mice to augment postischemic
neovascularization. Autologous stem cell transplantations are a goal of clinical PAD
therapies; and therefore, the ability of a diabetic pericyte transplantation to enhance
neovascularization should be investigated in future studies.
Other future directions include investigating the mechanisms for impaired
neovascularization and collateral artery engraftment in T2DM mice following
pericyte transplantation. If the mechanism for the diminished capacity of pericytes
to augment postischemic neovascularization in the diabetic environment are
understood, then therapies to overcome the impairment could be realized and
implemented in a clinical setting.
In conclusion, prospectively isolated skeletal muscle pericytes augment
postischemic neovascularization in wild type mice, but T2DM impairs the ability of
skeletal muscle pericytes to augment postischemic neovascularization. Following
the induction of limb ischemia, pericyte transplantation improves collateral artery
enlargement in wild type mice, but not in T2DM mice. Further, pericytes incorporate
into collateral vessels at a greater rate in wild type mice compared to T2DM mice,
and in vivo differentiation into Schwann cells occurs in both wild type and T2DM
mice. Pericytes are a novel cell type that may be beneficial for the treatment of
diabetic PAD, and studies should be conducted to determine ways to overcome the
diabetic impairment in this potential stem cell therapy.
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